Venetoclax

1:26
New data in myelodysplastic syndromes
Valeria Santini
1:16
Novel therapeutic for AML: CYC065 combinations
Mhairi Copland
4:17
Ibrutinib-rituximab for CLL: efficacious, but challenging toxicity profile
Jacqueline Barrientos
1:34
Venetoclax with mini-hyper-CVD for ALL
Nitin Jain
2:37
Allo-HSCT for CLL in the era of novel agents
Lindsey Roeker
1:28
Encouraging results for ibrutinib with venetoclax in R/R CLL
Nitin Jain
3:06
Durable responses to ibrutinib and venetoclax in R/R MCL: 3-year AIM update
Sasanka Handunnetti
2:25
Chemo-free regimens continue for CLL
Stephan Stilgenbauer
1:38
Ibrutinib and venetoclax upfront for high-risk CLL
Nitin Jain
1:10
VenBd in R/R MM: updated analysis of BELLINI
Philippe Moreau
3:01
VenBd shows significant improvement in PFS for R/R MM
Shaji Kumar
1:24
Predictive biomarkers of response to VenBd in R/R MM
Michael O’Dwyer
1:41
Oral time-limited duvelisib/venetoclax in R/R CLL
Matthew Davids
1:44
Cost-effectiveness of 12-month VenG for CLL
Matthew Davids
1:59
Acalabrutinib, venetoclax and obinutuzumab upfront for CLL
Matthew Davids
1:35
MRD in CLL: which settings is this most important?
Jennifer Woyach
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals